Business Context and Reporting Period
This Form 8-K Current Report was filed by Inogen, Inc. on April 11, 2024. The filing addresses a significant personnel change within the company's executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive separation and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of Dr. Stanislav Glezer, who served as Executive Vice President, R&D and Chief Medical Officer. Dr. Glezer and the Company mutually agreed to his separation, effective on or before May 3, 2024.
Guidance, Outlook, and Management Commentary
The Company expects to enter into a Separation Agreement with Dr. Glezer. The terms of this agreement will provide benefits consistent with his Amended and Restated Employment and Severance Agreement dated October 11, 2021. The material terms of the separation will be disclosed in a subsequent public filing. No financial guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the final terms of the Separation Agreement once disclosed in the subsequent filing.
- Confirm the exact effective date of Dr. Glezer's departure (on or before May 3, 2024).
- Monitor for announcements regarding the interim or permanent replacement for the Executive Vice President, R&D and Chief Medical Officer roles.
- Review the October 11, 2021 Employment and Severance Agreement to understand the baseline for the expected severance benefits.